Release Patterns of Pregnancy Associated Plasma Protein A (PAPP-A) in Patients with Acute Coronary Syndromes

Qin, Qiuping; Laitinen, Päivi; Majamaa‐Voltti, Kirsi; Eriksson, Susann; Kumpula, Eeva-Katri; Pettersson, Kim

doi:10.1080/140174302762659085

Cited by 57 publications

(41 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was suggested that measurement of PAPP-A could be used as an additional diagnostic and prognostic biomarker in patients presenting with chest pain. 209 Early studies showed that there are more patterns in patients with chest pain and it was suggested that it might not prove to be a useful early biomarker for diagnosis 210 but does appear to be prognostic. 211,212 Elevations of PAPP-A were reported to correlate with the extent of both coronary 213 and peripheral 214 vascular disease.…”

Section: Pregnancy-associated Plasma Protein Amentioning

confidence: 99%

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Collinson

Gaze²,

Thokala³

et al. 2013

Health Technol Assess

View full text Add to dashboard Cite

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.hta.ac.uk/ This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 09/22/16. The contractual start date was in August 2010. The draft report began editorial review in February 2012 and was accepted for publication in June 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Published by the NIHR Journals Library, produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk). Objectives: To test the diagnostic accuracy for detecting an acute myocardial infarction (AMI) using highly sensitive troponin assays and a range of new cardiac biomarkers of plaque destabilisation, myocardial ischaemia and necrosis; to test the prognostic accuracy for detecting adverse cardiac events using highly sensitive troponin assays and this range of new cardiac biomarkers; and to estimate the cost-effectiveness of using highly sensitive troponin assays or this range of new cardiac biomarkers instead of an admission and 10-to 12-hour troponin measurement. NIHR Journals LibraryDesign: Substudy of the point-of-care arm of the RATPAC (Randomised Assessment ...

show abstract

Section: Pregnancy-associated Plasma Protein Amentioning

confidence: 99%

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Collinson

Gaze²,

Thokala³

et al. 2013

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Finally, our results show that the molecular size of pregnancy-related PAPP-A is larger than that of ACSrelated PAPP-A, which further demonstrates that ACSrelated PAPP-A differs from pregnancy-related PAPP-A. In ACS, PAPP-A concentrations seldom exceed 30 mIU/L, which is equivalent to ϳ10 g/L (16,18 ). Such low concentrations make it difficult to detect ACS-related PAPP-A directly from blood samples by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analyses.…”

Section: Discussionmentioning

confidence: 69%

“…Samples were obtained from eight patients, four males [mean (SD) age, 63 (13) years] and four females [72 (16) years] with typical ST-elevation MI, at admission; at 1, 2, 4, 6, 24, 48 h afterward; and at discharge. In addition, three first-trimester serum samples (gestational ages, 9, 10, and 11 weeks) and one third-trimester serum sample (gestational age, 33 weeks) were included.…”

Section: Serum Samplesmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Distinction of Circulating Pregnancy-Associated Plasma Protein A in Myocardial Infarction and Pregnancy

et al. 2005

Self Cite

View full text Add to dashboard Cite

Background:In the blood of pregnant women, pregnancy-associated plasma protein A (PAPP-A) is present as a covalent complex with the proform of eosinophil major basic protein (proMBP). Recently, increased serum concentrations of PAPP-A have been found in acute coronary syndromes (ACS). The aim of this study was to investigate whether the circulating PAPP-A in ACS is the same as that in pregnancy. Methods: We developed two time-resolved immunofluorometric assays based on a relative epitope map constructed by the use of 17 monoclonal antibodies. One assay, which measured total PAPP-A, used two PAPP-A subunit-specific antibodies. The other assay, which measured PAPP-A/proMBP complex, used one proMBP subunit-specific antibody and one PAPP-A subunitspecific antibody. Serum samples from four patients with myocardial infarction (MI), three pregnant women in their first trimester, and one in her third trimester were fractionated by gel filtration on a Superose TM 6 precision column. The two assays were used to analyze fractions obtained by gel filtration as well as serum samples serially collected from four other MI patients. Results: Pregnancy-related PAPP-A was eluted as a single peak with a molecular mass of ϳ700 kDa, whereas ACS-related PAPP-A was also eluted as a single peak but with a molecular mass of ϳ530 kDa. Pregnancy-related PAPP-A was detected equally by the

show abstract

“…oraz Schoos i wsp. wykazali natomiast, że wzrost PAPP-A różni się pomiędzy pacjentami z OZW, a okno diagnostyczne mieści się w przedziale 2-30 godzin od początku bólu [26,27]. Lund i wsp.…”

Section: Wartość Diagnostyczna Osoczowego Białka Typu a Związanego Z unclassified

New methods in diagnostic and therapy Diagnostic value of circulating pregnancy-associated plasma protein A in atherosclerotic plaque rupture complications

Dudziak¹,

Majewski²,

Jerzykowska³

et al. 2011

pwki

View full text Add to dashboard Cite

Release Patterns of Pregnancy Associated Plasma Protein A (PAPP-A) in Patients with Acute Coronary Syndromes

Abstract: PAPP-A is an additional marker for ACS, but does not seem to be a useful early marker for acute myocardial infarction (AMI). The possible clinical utility of PAPP-A calls for extensive studies of chest pain patients using serial sampling combined with short- and long-term outcome studies.

Cited by 57 publications

References 8 publications

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Molecular Distinction of Circulating Pregnancy-Associated Plasma Protein A in Myocardial Infarction and Pregnancy

New methods in diagnostic and therapy Diagnostic value of circulating pregnancy-associated plasma protein A in atherosclerotic plaque rupture complications

Contact Info

Product

Resources

About